To further explore cellular and molecular functions of BCL6 in DLBCL and investigate its role in tumor maintenance in vivo, we devised a Doxycycline (DOX)-inducible CRISPR/Cas9 approach that enables conditional BCL6 knock-out in established DLBCL tumors (Supplementary Figure 1). The gene discussed is BCL6; the disease is neoplasm.